title: Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
abstract: Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.
authors.affiliation: Medical Oncology University Hospital, Service Oncologie, Boulevard Fleming, Besançon, Inserm U645, France. xavier.pivot@univ-fcomte.fr
authors.forename: Xavier B
authors.initials: XB
authors.lastname: Pivot
authors.forename: Rubi K
authors.initials: RK
authors.lastname: Li
authors.forename: Eva S
authors.initials: ES
authors.lastname: Thomas
authors.forename: Hyun-Cheol
authors.initials: HC
authors.lastname: Chung
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fein
authors.forename: Valorie F
authors.initials: VF
authors.lastname: Chan
authors.forename: Jacek
authors.initials: J
authors.lastname: Jassem
authors.forename: Fernando Hurtado
authors.initials: FH
authors.lastname: de Mendoza
authors.forename: Pralay
authors.initials: P
authors.lastname: Mukhopadyay
authors.forename: Henri H
authors.initials: HH
authors.lastname: Roché
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D004812:Epidemiologic Methods; D034261:Epothilones / Q000008:administration & dosage* / Q000009:adverse effects; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D034261:Epothilones; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D003841:Deoxycytidine; D000069287:Capecitabine; D066246:ErbB Receptors; C430592:ixabepilone; D005472:Fluorouracil